IL5 and eosinophilic granulomatosis with polyangiitis: This review highlights the molecular roles of eosinophils and IL-5 in EGPA pathophysiology and summarizes the mechanisms and clinical benefits of the anti-IL-5 therapies mepolizumab and benralizumab.